Muscle Relaxants Tied to Increased Risk of Respiratory Complications When Administered During General Anesthesia

By Kaitlyn D’Onofrio - Last Updated: April 12, 2023

Using neuromuscular blocking drugs in general anesthesia may be tied to a greater likelihood of postoperative pulmonary complications, according to new researchers. 

Advertisement

The prospective observational cohort study, POPULAR, which was published in The Lancet Respiratory Medicine, included 22,803 patients (aged ≥ 18 years) from 211 hospitals in 28 countries in Europe who received general anesthesia during any inpatient procedure (except cardiac surgery). Researchers found the use of muscle relaxants was associated with more frequent pulmonary complications postoperation in general anesthesia patients (7.6%, n = 1,658) (odds ratio [OR], 1.86). Neither neuromuscular monitoring (OR, 1.31) nor reversal agents (OR, 1.23) decreased the risk of postoperative respiratory complications. Using sugammadex as opposed to neostigmine for reversal (OR, 1.03) or extubation at a train-of-four ratio of 0.9 or more (OR, 1.03) also did not lower the chances of pulmonary complications postoperation. 

POPULAR was led by the Technical University of Munich (TUM) and funded by the European Society of Anaesthesiology. 

Anesthesia may result in some muscle relaxation on its own, but a second medicine is often used to relax the whole body. In some surgeries this may help prevent injury; in others, it may allow for easy joint movement.  

“These drugs are particularly needed when operating on a patient’s chest or abdomen. They are also used to protect the vocal cords from injury when a tube is placed in the airway to allow artificial ventilation,” said Professor Manfred Blobner, an anesthesiologist at TUM’s Clinic for Anesthesiology and Intensive Care, as well as chair of the POPULAR steering committee. 

The study authors concluded, “Anaesthetists must balance the potential benefits of neuromuscular blockade against the increased risk of postoperative pulmonary complications.” 

Sources: EurekAlertThe Lancet Respiratory Medicine

Advertisement